NCT06768632 - Bioequivalence Test of Eltrombopag Olamine Tablets in Humans Under Fasting State | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 2, 2020

Primary Completion Date

April 27, 2020

Study Completion Date

December 30, 2023

Conditions

Thrombocytopenia

Interventions

DRUG

Group 1: single-dose of test formulation+single-dose of reference formulation

Eltrombopag Tablets is a small molecule non peptide thrombopoietin receptor agonist.

DRUG

Group 2: single-dose of reference formulation+single-dose of test formulation

Eltrombopag Tablets is a small molecule non peptide thrombopoietin receptor agonist.

Trial Locations (1)

Lianyungang First People's Hospital, Lianyungang